2
Lindis Biotech develops immunotherapy against bladder cancer
Ein Dokument
mehr
Storys zum Thema Medizinische Behandlung
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
Sysmex Inostics Presents Data at AACR Demonstrating SafeSEQ NGS Liquid Biopsy Delivers Equivalent Performance to the Extensively Clinically Validated OncoBEAM dPCR Technology for NSCLC Patients
Baltimore, MD, USA (ots) - Sysmex Inostics, Inc., a global leader of the liquid biopsy revolution for oncology, is presenting the poster “Clinical evaluation of NGS-based liquid biopsy testing in non-small cell lung cancer (NSCLC) patients” at the 112th Annual Meeting of the American Association for Cancer ...
mehrIntroducing DocMorris Adipositas Care (Obesity Care), a digital hub empowering people with obesity to find relevant care for a better quality of life
Berlin (ots) - The Novo Nordisk and Zur Rose Group collaboration presents DocMorris Adipositas Care, a digital hub which provides people living with obesity a new way to find the right care. Adipositas Care thoughtfully empowers people living with obesity by enabling them to learn about obesity and discover possible ...
mehrGerman Green Technology from DAS Environmental Experts for Swiss DSM Nutritional Products AG / Moving Bed Biofilm Reactor for sustainable wastewater treatment for the food industry
Dresden (ots) - Increasing production capacities have stretched the existing wastewater treatment plant at the chemical company DSM Nutritional Products in Switzerland to its limits. Wastewater characteristics of the chemical industry with strict regulations of the beverage and food industry - the experts of German ...
mehrSocial Stigma Burdens Innovative Lung Cancer-Therapies, Study Says
Social Stigma Burdens Innovative Lung Cancer-Therapies, Study Says Social stigma towards diseases such as lung cancer can hinder patients to seek treatment and, as a consequence, negatively affects the diffusion of innovative therapies, according to a recently published study. “Lung cancer carries a unique social stigma due to its association with cigarette smoking, and hence is often seen as a smoker’s disease, ...
mehrFirst pocket inhaler for Covid-19 and other viral mutations
Buochs (ots) - DG-Nika AG – a new approach to therapy & proactive protection from the pandemic The corona pandemic continues to pose a global threat: To date, it has been possible to vaccinate only a small fraction of the total population. On top of that, there is acute danger from mutations of this virus. Against this backdrop, the DG-Nika AG research team has developed a solution for a new approach to protecting the ...
mehr
- 2
B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®
mehr - 3
World Cancer Day: Start-ups at the IZB develop innovative cancer drugs and diagnostic tools
Ein Dokumentmehr COVID-19: Use rapid tests to identify important biomarkers and predict the course of the disease
Moers (ots) - Whether it’s a lung embolism or a heart attack – an infection with coronavirus can have life-threatening consequences. But how badly will different patients be affected by COVID-19? This can be determined by certain biomarkers. nal von minden GmbH’s biomarker rapid tests from Germany deliver reliable results in just 15 minutes. An infection with ...
mehrTechnische Universität München
Breathing rate predicts therapeutic benefits for heart patients
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36385/ NEWS RELEASE Discovering a forgotten biosignal Breathing rate predicts therapeutic benefits for heart patients Conditions causing arrhythmia are among ...
mehrSysmex Inostics Presents Data at the American Society of Hematology Annual Meeting Demonstrating Exquisite Sensitivity of SafeSEQ NGS Technology for Detection of Measurable Residual Disease in Acute Myeloid Leukemia
Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based, high-sensitivity molecular testing for oncology, is presenting the poster "Ultrasensitive Measurable Residual Disease (MRD) Detection in Acute Myeloid Leukemia (AML) Using a Targeted Next Generation Sequencing (NGS) Panel" at ...
mehrTechnische Universität München
WHO guidelines on physical activity call for more exercise
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.sg.tum.de/en/news-en/news-singleview-fakultaet-en/article/prof-oberhoffer-fritz-fordert-nach-aktuellen-who-empfehlungen-kinder-und-jugendliche-muessen-sich-en/ High resolution images: https://mediatum.ub.tum.de/1581167 NEWS RELEASE WHO guidelines on physical ...
mehr
Regulatory breakthrough for BrainRepair UG start-up - Stem cell treatment for newborns /EMA Orphan Drug Designation is followed by agreement on Paediatric Investigation Plan
mehrSysmex Inostics' Liquid Biopsy Testing Benefits Metastatic Pancreatic Cancer Patient Management
Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating cell-free tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study investigating the utility of cfDNA-based markers using the highly sensitive OncoBEAM RAS assay, an enhanced ...
mehrSysmex Inostics' OncoBEAMTM RAS CRC testing supports clinical outcome improvements for metastatic colorectal cancer patients rechallenged with anti-EGFR therapy
Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study evaluating RAS mutation status in circulating tumor DNA (ctDNA) of colorectal cancer (CRC) patients undergoing anti-EGFR ...
mehrEffectiveness and efficiency of targeted intra-operative single dose radiotherapy for breast cancer patients confirmed
Jena, Germany (ots) - New long-term results from the international TARGIT-A breast cancer study, based on ZEISS technology, have been published [1] Use of targeted intra-operative radiotherapy (TARGIT), as a single dose - with ZEISS INTRABEAM - directly after removal of a tumor, confirmed as non-inferior, when ...
mehrSysmex-Inostics Colorectal Cancer Blood-Based OncoBEAMTM RAS CE-IVD Test Shows Concordance with Standard of Care Tissue-Based RAS Testing
Baltimore, Maryland (ots) - Sysmex-Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study evaluating the performance of plasma RAS mutation testing with OncoBEAM RAS CRC as compared to standard of care ...
mehrVersameb raises CHF 6 million and strengthens team to advance its VERSagile technology platform towards clinical trials
Basel, Switzerland (ots) - Versameb AG, a biopharmaceutical company developing innovative ribonucleic acid (RNA) therapeutics, announced today the closing of a CHF 6 million seed financing round. Versameb further strengthens its team by the appointment of Dr. Klaas P. Zuideveld as Chief Development Officer effective ...
mehr
Technische Universität München
Nutrition in the days of COVID
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36110/ Images for journalists: https://mediatum.ub.tum.de/1552085 NEWS RELEASE An interview with Prof. Hans Hauner about COVID-19 and nutritional medicine Nutrition in the days of COVID The current Corona outbreak affects nearly all aspects of medicine and of everyday ...
mehr- 2
Innovation: Intelligent bacteria demonstrate high efficacy in the treatment of widespread disease irritable bowel syndrome with typical symptoms of recurrent diarrhoea, abdominal pain, bloating and constipation
mehr Eleva's drug candidate to be examined for use in Covid-19 treatment
Freiburg (ots) - Eleva, a manufacturer of superior biologics, is exploring the potential of one of its drug candidates for first-in-line therapy of Covid-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of Covid-19. Eleva has developed factor H previously for a different indication and taken it through ...
mehrTechnische Universität München
A disease trigger for pancreatitis has been identified
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 8161/ 71-5403 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36036/ High resolution images: https://mediatum.ub.tum.de/1545776 NEWS RELEASE A Calcium channel is involved in the development of pancreatitis A disease trigger for pancreatitis has been identified One factor ...
mehrTechnische Universität München
Improving immunotherapy for cancer
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 8161/ 71-5403 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36023/ High resolution images: https://mediatum.ub.tum.de/1544218 NEWS RELEASE Cause for the lack of immune defense against tumors discovered Improving immunotherapy for cancer One of the reasons why cancer develops is because regulatory cells inhibit the body's ...
mehrTechnische Universität München
Protective ventilation: Computational model of the lung could significantly reduce the number of deaths from Covid-19 and ARDS
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/35990/ High resolution images: https://mediatum.ub.tum.de/1543821 Video of the research on the ...
mehr
Technische Universität München
Crohn's disease: Preserving inflammation-free phases
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 8161/ 71-5403 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/35979/ High resolution images: https://mediatum.ub.tum.de/1543290 NEWS RELEASE Early detection of Crohn’s disease flare-ups leads to improved therapy options Preserving inflammation-free phases Crohn’s ...
mehrElastrin Therapeutics develops new approach against "Inflammatory Storm" that kills most Corona patients
Greenville South Carolina (ots) - A previously untested approach to preventing the most severe outcomes of lung diseases, including COVID-19, has been developed by Elastrin Therapeutics based on targeting damaged elastic fiber that leads to impaired lung function. The company has developed the world's first ...
mehrHitachi Medical Systems Europe Holding AG
Hitachi Medical Systems Europe launches "ARIETTA 750", the new model from the ARIETTA series of diagnostic ultrasound platforms / This model inherited premium class technologies
mehrSysmex Inostics' updated SafeSEQ Breast Cancer Panel advances novel clinical uses of ctDNA through quantitative testing
Baltimore, Maryland (ots) - Building on the ultra-high sensitivity SafeSEQ Breast Cancer Panel circulating tumor DNA (ctDNA) test launched at the American Association of Cancer Research 2019 annual meeting, Sysmex Inostics has updated the test to provide additional key information for investigation of the validity ...
mehrInspirational talks form SIRION Biotech, CLS Behring and the German Accelerator at the 13th Biotech Press Lounge at the IZB
Ein DokumentmehrTechnische Universität München
Major project for Munich neurosciences
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 8161 71 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/35908/ High resolution images: https://mediatum.ub.tum.de/1537625 NEWS RELEASE CLINSPECT-M: Clinical mass spectrometry center for molecular brain research Major project for Munich neurosciences In a joint ...
mehr
Vorherige123456Nächste